TrialJournal of women's health (2002)2022

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.

Elizabeth A Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.